NOVN
-24.84%(-0.03)
Open
0.14
Prev Close
0.13
Day High
0.14
Day Low
0.08
Volume
6.9M
Avg Volume
1.0M
52W High
3.33
52W Low
0.08
ANALYST COVERAGE3 analysts
BUY
Buy
267%
Hold
133%
2 Buy (67%)1 Hold (33%)0 Sell (0%)
Full report →
Key MetricsTTM
Market Cap$2.64M
Revenue TTM$24.71M
Net Income TTM$999.0K
Free Cash Flow-$39.27M
Gross Margin68.7%
Operating Margin-149.9%
Net Margin-82.9%
Return on Equity-170.7%
Return on Assets-21.7%
Debt / Equity0.85
Current Ratio0.91
EPS TTM$-0.89
PRICE
Prev Close
0.13
Open
0.14
Day Range0.08 – 0.14
0.08
0.14
52W Range0.08 – 3.33
0.08
3.33
0% of range
VOLUME & SIZE
Avg Volume
1.0M
FUNDAMENTALS
P/E Ratio
-0.1x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.11
Market-like
TECHNICAL
RSI (14)
25
Oversold
Upcoming Events
EEarnings Report
Tomorrow
May 23
DEx-Dividend
In 90 days
Aug 20
PDividend Pay
In 119 days
Sep 18

NOVN News

About

novan, inc. is a clinical-stage biotechnology company focused on leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. we believe that our ability to conveniently deploy nitric oxide in a solid form, on demand and in localized formulations allows us the potential to significantly improve patient outcomes in a variety of diseases.

Industry
Pharmaceutical Preparation Manufacturing
CEO
Paula Stafford
John A. Donofrio Jr.Executive Vice President & Chief Operating Officer
John GayChief Financial Officer, Principal Accounting Officer & Corporation Sec.